A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia

The document titled "A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia" from October 2019 summarizes the findings from in vitro and clinical trials of clascoterone, a topical androgen receptor antagonist being investigated for the treatment of androgenetic alopecia. The studies found that clascoterone is well-tolerated, has minimal systemic exposure, and demonstrated a notable hair growth signal comparable to minoxidil. The combination of research and publications, strong letters of recommendation, dermatology rotations, high USMLE scores, and a reputable postgraduate training were found to give international applicants the highest chance of matching to dermatology residency in the US. A survey-based comparison of sun safety practices found that those who seek skin cancer screenings are more likely to practice proper photoprotective practices than a randomly sampled population.